Back

Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity sc

28 August 2023 (15:15 - 15:50)
Organised by: Logo
Congress Presentation Part of: Antidiabetic medications and cardiovascular disease Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Gary Tse

Hong Kong Metropolitan University, Hong Kong (China)

6 More presentations in this session

Presentation thumbnail
Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study
Assistant Professor Y. Chen (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
Professor Y. Oh (Seoul, KR)
Abstract Slides
Presentation thumbnail
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
Doctor R. Kani (Kamogawa, JP)
Abstract Slides Video
Presentation thumbnail
GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study
Ms K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor
Doctor C. Chen (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Antidiabetic medications and cardiovascular disease

The Event

Event poster

ESC Congress 2023

28 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
The effect of SGLT2 inhibitor on clinical outcomes in patients with type 2 diabetes and atrial fibrillation
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
thumbnail
Congress Presentation
Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources